The event will take place on September 30, 2026 beginning at 11am ET, and will feature presentations by ProQR management and Gideon Hirschfield, MA (Oxon), MB BChir (Cantab), FRCP, PhD, Professor of Gastroenterology and Hepatology at the Toronto Centre for Liver Disease. The event will provide an in-depth review of the role of bile acids and NTCP modulation in cholestatic liver disease, with a focus on biliary atresia. ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease.
Event Details and Registration
- Title: NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing
- Date & Time: September 30, 2026 beginning at 11 am ET until approximately 12 pm ET
- Virtual format: Webcast presentations and Q&A with covering analysts
- Registration: https://lifescievents.com/event/prk62s0/(external link)
KOL Biography
Gideon Hirschfield, MA (Oxon) MB BChir (Cantab) FRCP PhD, Professor of Gastroenterology and Hepatology at the Toronto Centre for Liver Disease
Prof. Hirschfield is an experienced and highly focused clinician-scientist specializing in autoimmune and cholestatic liver diseases. He holds the Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the Toronto Centre for Liver Disease, Toronto General Hospital, and serves as a Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Toronto.
Prof. Hirschfield completed undergraduate studies in Medicine from the Universities of Oxford and Cambridge and subsequently was awarded a PhD from the University of London in 2006. He completed specialist training in Internal Medicine, Gastroenterology and Hepatology in London, Cambridge and Toronto.
An internationally recognized expert, Prof. Hirschfield has published over 350 peer-reviewed articles, including lead authorship in high-impact journals such as the New England Journal of Medicine, The Lancet, and Nature Genetics.
His research focuses on advancing therapies for autoimmune and cholestatic liver diseases with the clear goal of preventing the need for transplantation alongside improving patient quality of life.
